Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Formoterol/Fluticasone vs Salmeterol/Fluticasone in COPD
NCT01393145Phase 3Withdrawn
- Sponsor
- Aché Laboratórios Farmacêuticos
- Start
- Aug 2011
- Primary completion
- Aug 2012
- Modality
- Orthosteric Ligands
01
Overview
Phase 3, randomised, open-label trial in chronic obstructive pulmonary disease (COPD) comparing Formoterol/Fluticasone with Salmeterol/Fluticasone (2 arms). Primary endpoint: Changes in pre-bronchodilator forced expiratory volume in first second at 24 weeks. Planned start Aug 2011; status: withdrawn.
02
Drugs
formoterolfluticasone propionate nasal spray
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01393145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01393145.